JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

Search

Eli Lilly and Co.

Closed

SectorHealthcare

767.47 0.86

Overview

Share price change

24h

Current

Min

749.69

Max

773.7

Key metrics

By Trading Economics

Income

-6.1B

2.8B

Sales

-804M

13B

P/E

Sector Avg

66.239

40.048

Dividend yield

0.66

Profit margin

21.678

Employees

47,000

EBITDA

-2B

4.2B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+34.95% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.66%

2.45%

Next Earnings

7 Aug 2025

Next Dividend date

10 Sept 2025

Next Ex Dividend date

15 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-98B

730B

Previous open

766.61

Previous close

767.47

News Sentiment

By Acuity

60%

40%

331 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Eli Lilly and Co. Chart

Past performance is not a reliable indicator of future results.

Related News

17 Jun 2025, 11:56 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

27 May 2025, 14:41 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

30 Jul 2025, 10:38 UTC

Market Talk

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

29 Jul 2025, 17:05 UTC

Earnings

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

29 Jul 2025, 16:55 UTC

Earnings

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

29 Jul 2025, 13:35 UTC

Earnings

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

29 Jul 2025, 11:39 UTC

Earnings

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

25 Jul 2025, 12:49 UTC

Acquisitions, Mergers, Takeovers

Lilly Completes Acquisition Of Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

24 Jul 2025, 12:02 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Expects to Complete Verve Acquisition on July 25 >LLY VERV

24 Jul 2025, 12:01 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: About 55.7% of Verve Shares Tendered >LLY VERV

24 Jul 2025, 12:00 UTC

Acquisitions, Mergers, Takeovers

Lilly and Verve Announce Expiration of Verve Tender Offer

9 Jul 2025, 09:17 UTC

Hot Stocks

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

17 Jun 2025, 14:02 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 Jun 2025, 12:12 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 Jun 2025, 11:01 UTC

Acquisitions, Mergers, Takeovers

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 Jun 2025, 10:47 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 Jun 2025, 10:47 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 Jun 2025, 10:46 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 Jun 2025, 10:45 UTC

Acquisitions, Mergers, Takeovers

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 Jun 2025, 09:33 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

11 Jun 2025, 09:45 UTC

Market Talk

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

29 May 2025, 01:00 UTC

Top News

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28 May 2025, 18:09 UTC

Earnings

Heart Disease Could Be a Goner When These New -2-

28 May 2025, 18:09 UTC

Earnings

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27 May 2025, 14:02 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27 May 2025, 14:01 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27 May 2025, 14:00 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27 May 2025, 14:00 UTC

Acquisitions, Mergers, Takeovers

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20 May 2025, 14:08 UTC

Earnings

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12 May 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

Peer Comparison

Price change

Eli Lilly and Co. Forecast

Price Target

By TipRanks

34.95% upside

12 Months Forecast

Average 1,028.8 USD  34.95%

High 1,190 USD

Low 883 USD

Based on 19 Wall Street analysts offering 12 month price targets forEli Lilly and Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

19 ratings

17

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

N/A / 884.54Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

331 / 374 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.